# Study on the prediction of prognosis of patients with acute liver failure treated with artificial liver by serum NLR and IL-6 levels

## TL;DR

This study shows that higher levels of IL-6 and NLR in the blood are linked to worse outcomes in patients with acute liver failure treated with artificial liver support.

## Contribution

The study identifies IL-6 and NLR as potential biomarkers for predicting prognosis in acute liver failure patients undergoing artificial liver treatment.

## Key findings

- Death group patients had significantly higher IL-6 and NLR levels compared to the survival group.
- The AUC for IL-6 and NLR individually predicting prognosis were 0.727 and 0.789, respectively.
- Combining IL-6 and NLR improved the AUC to 0.889 for predicting treatment outcomes.

## Abstract

To observe the relationship between the expression of serum interleukin-6 (IL-6) and neutrophil/lymphocyte ratio (NLR) and the prognosis of patients with acute liver failure (ALF) treated with artificial liver.

80 patients with ALF from January 2021 to October 2023 were included. All of them received artificial liver system treatment. All of the included subjects completed the effective follow-up for three months. The patients were followed up until April 30, 2023. According to the disease outcomes of patients after the end of follow-up, they were divided into a survival group and a death group. The serum IL-6 and NLR expressions of the two groups were compared, and the relationship between serum IL-6 and NLR expressions and the prognosis of patients with ALF treated with artificial liver was analysed.

The expression levels of serum IL-6 and NLR in the death group were higher (P<0.05). The high expressions of serum IL-6 and NLR might be a risk factor for the increased risk of death in patients with ALF after treatment (P<0.05). The receiver operating characteristic (ROC) curve indicated that the area under the curve (AUC) of fasting serum IL-6 and NLR expressions in patients with ALF predicting the prognosis of artificial liver treatment were 0.727 and 0.789. When the AUC of serum IL-6 combined with NLR predicted the prognosis of artificial liver treatment in patients with ALF, it was 0.889.

The expression of serum IL-6 and NLR is correlated with the prognosis of patients with ALF treated with artificial liver.